Universal Beteiligungs und Servicegesellschaft mbH Purchases New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 178,850 shares of the biopharmaceutical company's stock, valued at approximately $3,733,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.15% of Catalyst Pharmaceuticals as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after buying an additional 390,116 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company's stock worth $56,477,000 after purchasing an additional 180,100 shares during the period. Castlekeep Investment Advisors LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth about $37,494,000. Bank of America Corp DE boosted its holdings in shares of Catalyst Pharmaceuticals by 139.5% during the fourth quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock worth $32,741,000 after purchasing an additional 913,843 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Catalyst Pharmaceuticals by 8.7% during the fourth quarter. Northern Trust Corp now owns 1,503,566 shares of the biopharmaceutical company's stock worth $31,379,000 after purchasing an additional 119,766 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Up 0.3%

NASDAQ:CPRX traded up $0.07 during mid-day trading on Thursday, reaching $25.36. The company's stock had a trading volume of 929,880 shares, compared to its average volume of 1,112,398. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.75 and a 1 year high of $26.16. The stock has a fifty day moving average of $23.60 and a 200-day moving average of $22.71. The firm has a market capitalization of $3.09 billion, a PE ratio of 21.49, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,000 shares of the firm's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the transaction, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,627,468.99. This trade represents a 38.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on CPRX shares. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Stephens restated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, Robert W. Baird boosted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.